Johnson & Johnson $JNJ Stock Holdings Cut by Appleton Partners Inc. MA

Appleton Partners Inc. MA reduced its position in shares of Johnson & Johnson (NYSE:JNJ) by 2.2% in the second quarter, HoldingsChannel.com reports. The firm owned 46,980 shares of the company’s stock after selling 1,065 shares during the period. Appleton Partners Inc. MA’s holdings in Johnson & Johnson were worth $7,176,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Highline Wealth Partners LLC boosted its stake in Johnson & Johnson by 51.8% during the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock valued at $42,000 after purchasing an additional 86 shares in the last quarter. Stone House Investment Management LLC bought a new stake in shares of Johnson & Johnson during the 1st quarter worth $47,000. 1248 Management LLC bought a new stake in shares of Johnson & Johnson during the 1st quarter worth $48,000. von Borstel & Associates Inc. bought a new stake in shares of Johnson & Johnson during the 1st quarter worth $49,000. Finally, Harvest Fund Management Co. Ltd bought a new stake in shares of Johnson & Johnson during the 1st quarter worth $52,000. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $188.95 on Wednesday. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $189.92. The business has a fifty day simple moving average of $177.04 and a 200 day simple moving average of $163.18. The firm has a market cap of $455.06 billion, a price-to-earnings ratio of 20.21, a P/E/G ratio of 2.40 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.09. The business had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.Johnson & Johnson’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same period last year, the company earned $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, sell-side analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio is presently 55.61%.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on JNJ shares. Wells Fargo & Company set a $212.00 price objective on Johnson & Johnson and gave the stock an “overweight” rating in a research note on Friday. UBS Group set a $198.00 price objective on Johnson & Johnson in a research note on Friday. Morgan Stanley raised their price objective on Johnson & Johnson from $171.00 to $176.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 17th. Royal Bank Of Canada raised their price objective on Johnson & Johnson from $181.00 to $185.00 and gave the stock an “outperform” rating in a research note on Thursday, July 17th. Finally, Wall Street Zen upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Saturday, September 13th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $189.88.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 0.16% of the stock is owned by insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.